EU 25: regulatory crisis of confidence looms
This article was originally published in Clinica
Executive Summary
There could be a new crisis of confidence in the European medical device regulatory system next year with the advent of the 10 new member states to the EU, unless the regulators agree to new inspection activities to ensure this is averted. That was the thrust of the message put forward by Malcolm Carlisle, group managing director at Eschmann Holdings at the 11th Annual ABHI Conference on Medical Device Regulation.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.